keyword
MENU ▼
Read by QxMD icon Read
search

Oritavancin

keyword
https://www.readbyqxmd.com/read/28642145/new-and-improved-a-review-of-novel-antibiotics-for-gram-positive-bacteria
#1
REVIEW
Mohamed Abbas, Mical Paul, Angela Huttner
BACKGROUND: The number of antibiotics in the pipeline targeting Gram-positive pathogens has increased in recent years. AIMS: This narrative review aims to provide a summary of existing evidence on efficacy, microbiologic spectrum, and safety of novel systemic antibiotics that have either recently been licenced or completed phase III trials, and possess activity predominantly against Gram-positive organisms. SOURCES: A review of the published literature via the MEDLINE database was performed...
June 19, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28543367/successful-treatment-of-methicillin-susceptible-staphylococcus-aureus-osteomyelitis-with-oritavancin
#2
Dino J Delaportas, Sandy J Estrada, Matthew Darmelio
Staphylococcus aureus remains the most common causative pathogen in osteomyelitis. New or alternate therapies are often needed to adequately treat S. aureus infections in patients with drug allergies, treatment failures, or drug interactions. Oritavancin is a novel long-acting lipoglycopeptide approved by the Food and Drug Administration (FDA) in 2014 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). With a terminal half-life of 8 to 10 days, oritavancin dosing regimens with infrequent parenteral administration now exist to treat infectious diseases such as osteomyelitis that would otherwise require daily dosing of intravenous antimicrobials for weeks; however clinical experience is lacking...
May 23, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28507244/inhibition-of-staphylococcus-aureus-cell-wall-biosynthesis-by-desleucyl-oritavancin-a-quantitative-peptidoglycan-composition-analysis-by-mass-spectrometry
#3
James D Chang, Erin E Foster, Aanchal N Thadani, Alejandro J Ramirez, Sung Joon Kim
Oritavancin is a lipoglycopeptide antibiotic that exhibits potent activities against vancomycin-resistant Gram-positive pathogens. Oritavancin differs from vancomycin by a hydrophobic side chain attached to the drug disaccharide, which forms a secondary-binding site to enable oritavancin binding to the cross-linked peptidoglycan in cell wall. The mode of action of secondary-binding site was investigated by measuring the changes in the peptidoglycan composition of Staphylococcus aureus grown in presence of desleucyl-oritavancin at sub-inhibitory concentration using liquid chromatography-mass spectrometry (LC-MS)...
May 15, 2017: Journal of Bacteriology
https://www.readbyqxmd.com/read/28480909/inhibition-of-d-ala-incorporation-into-wall-teichoic-acid-in-staphylococcus-aureus-by-desleucyl-oritavancin
#4
J Chang, L Coffman, S J Kim
The mode of action for desleucyl-oritavancin was investigated by adding an antibiotic to Staphylococcus aureus during its growth in a defined medium containing l,d-[1-(15)N]Ala and l-[1-(13)C]Lys, or d-[1-(15)N]Ala. (13)C{(15)N} and (15)N{(13)C} rotational-echo double resonance NMR determined that desleucyl-oritavancin inhibited the incorporation of d-[1-(15)N]Ala into wall teichoic acid.
May 8, 2017: Chemical Communications: Chem Comm
https://www.readbyqxmd.com/read/28480266/efficacy-and-safety-of-oritavancin-relative-to-vancomycin-for-patients-with-acute-bacterial-skin-and-skin-structure-infections-absssi-in-the-outpatient-setting-results-from-the-solo-clinical-trials
#5
Thomas P Lodise, Mark Redell, Shannon O Armstrong, Katherine A Sulham, G Ralph Corey
BACKGROUND: The objective of this analysis was to evaluate the efficacy and safety of oritavancin compared with vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSIs) who received treatment in the outpatient setting in the Phase 3 SOLO clinical trials. METHODS: SOLO I and SOLO II were 2 identically designed comparative, multicenter, double-blind, randomized studies to evaluate the efficacy and safety of a single 1200-mg dose of intravenous (IV) oritavancin versus 7-10 days of twice-daily IV vancomycin for the treatment of ABSSSI...
2017: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/28406838/managing-acute-bacterial-skin-and-skin-structure-infections-focus-on-new-lipoglycopeptides
#6
Allison M Bell, S Travis King, Katie E Barber, Kim G Adcock, Jamie L Wagner, Kayla R Stover
Acute bacterial skin and skin structure infections (ABSSSI) are some of the most commonly encountered infections worldwide. Hospitalizations as a result of ABSSSI are associated with high mortality. This article discusses the role of oritavancin and dalbavancin, two new lipoglycopeptides, in the context of the other I.V. available standard therapy options.
May 12, 2017: Nurse Practitioner
https://www.readbyqxmd.com/read/28386776/real-world-experience-with-oritavancin-therapy-in-invasive-gram-positive-infections
#7
Cassie L Stewart, Michelle S Turner, Jeremy J Frens, Cynthia B Snider, Jordan R Smith
INTRODUCTION: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited. METHODS: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections...
June 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28368603/hidden-mode-of-action-of-glycopeptide-antibiotics-inhibition-of-wall-teichoic-acid-biosynthesis
#8
Manmilan Singh, James Chang, Lauryn Coffman, Sung Joon Kim
Glycopeptide antibiotics inhibit the peptidoglycan biosynthesis in Gram-positive bacteria by targeting lipid II. This prevents the recycling of bactoprenol phosphate, the lipid transporter that is shared by peptidoglycan and wall teichoic acid biosyntheses. In this study, we investigate the effects of glycopeptide antibiotics on peptidoglycan and wall teichoic acid biosynthesis. The incorporation of d-[1-(13)C]alanine, d-[(15)N]alanine, and l-[1-(13)C]lysine into peptidoglycan and wall teichoic acid in intact whole cells of Staphylococcus aureus was measured using (13)C{(15)N} and (15)N{(13)C} rotational-echo double resonance NMR...
April 14, 2017: Journal of Physical Chemistry. B
https://www.readbyqxmd.com/read/28273381/role-of-combination-antimicrobial-therapy-for-vancomycin-resistant-enterococcus-faecium-infections-review-of-the-current-evidence
#9
Juwon Yim, Jordan R Smith, Michael J Rybak
Enterococcus species are the second most common cause of nosocomial infections in the United States and are particularly concerning in critically ill patients with preexisting comorbid conditions. Rising resistance to antimicrobials that were historically used as front-line agents for treatment of enterococcal infections, such as ampicillin, vancomycin, and aminoglycosides, further complicates the treatment of these infections. Of particular concern are Enterococcus faecium strains that are associated with the highest rate of vancomycin resistance...
March 8, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28221772/desleucyl-oritavancin-with-a-damaged-d-ala-d-ala-binding-site-inhibits-the-transpeptidation-step-of-cell-wall-biosynthesis-in-whole-cells-of-staphylococcus-aureus
#10
Sung Joon Kim, Manmilan Singh, Shasad Sharif, Jacob Schaefer
We have used solid-state nuclear magnetic resonance to characterize the exact nature of the dual mode of action of oritavancin in preventing cell-wall assembly in Staphylococcus aureus. Measurements performed on whole cells labeled selectively in vivo have established that des-N-methylleucyl-N-4-(4-fluorophenyl)benzyl-chloroeremomycin, an Edman degradation product of [(19)F]oritavancin, which has a damaged d-Ala-d-Ala binding aglycon, is a potent inhibitor of the transpeptidase activity of cell-wall biosynthesis...
March 14, 2017: Biochemistry
https://www.readbyqxmd.com/read/28159446/in-vitro-activity-of-oritavancin-against-gram-positive-pathogens-isolated-in-canadian-hospital-laboratories-from-2011-to-2015
#11
James A Karlowsky, Andrew J Walkty, Melanie R Baxter, Francis F Arhin, Gregory Moeck, Heather J Adam, George G Zhanel
Gram-positive bacterial pathogens isolated from patient specimens submitted to 15 Canadian hospital laboratories from 2011 to 2015 were tested in the coordinating laboratory for susceptibility to oritavancin and comparative antimicrobial agents using the Clinical and Laboratory Standards Institute M07-A10 (2015) broth microdilution method. Oritavancin's in vitro activity was equivalent to, or more potent than, vancomycin, daptomycin, linezolid, and tigecycline against methicillin-susceptible Staphylococcus aureus (n=2680; oritavancin MIC90, 0...
April 2017: Diagnostic Microbiology and Infectious Disease
https://www.readbyqxmd.com/read/28155918/surface-mediated-cooperative-interactions-of-drugs-enhance-mechanical-forces-for-antibiotic-action
#12
Joseph W Ndieyira, Joe Bailey, Samadhan B Patil, Manuel Vögtli, Matthew A Cooper, Chris Abell, Rachel A McKendry, Gabriel Aeppli
The alarming increase of pathogenic bacteria that are resistant to multiple antibiotics is now recognized as a major health issue fuelling demand for new drugs. Bacterial resistance is often caused by molecular changes at the bacterial surface, which alter the nature of specific drug-target interactions. Here, we identify a novel mechanism by which drug-target interactions in resistant bacteria can be enhanced. We examined the surface forces generated by four antibiotics; vancomycin, ristomycin, chloroeremomycin and oritavancin against drug-susceptible and drug-resistant targets on a cantilever and demonstrated significant differences in mechanical response when drug-resistant targets are challenged with different antibiotics although no significant differences were observed when using susceptible targets...
February 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28137232/synthesis-properties-and-mechanism-of-action-of-new-generation-of-polycyclic-glycopeptide-antibiotics
#13
Eugenia N Olsufyeva, Anna N Tevyashova
The increased resistance of glycopeptide based antibiotics has become a serious problem for the chemotherapy of infections triggered by resistant Gram-positive bacteria. This has motivated the urgent sincere efforts to develop potent glycopeptide-based antibiotics in both academy and industry research laboratories. Understanding of the mechanism of action of natural and modified glycopeptides is considered as the basis for the rational design of compounds with valuable properties to achieve the fundamental results...
January 30, 2017: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/28134678/what-is-new-in-the-management-of-skin-and-soft-tissue-infections-in-2016
#14
Garyphallia Poulakou, Efthymia Giannitsioti, Sotirios Tsiodras
PURPOSE OF REVIEW: Skin and soft tissue infections (SSTIs) are the most frequent infectious cause of referrals to emergency departments and hospital admissions in developed world, contributing to significant morbidity and healthcare expenditures. We sought to review recent literature covering epidemiology and management of SSTIs. RECENT FINDINGS: Incidence trends of SSTIs were increasing worldwide with Staphylococcus aureus and streptococci predominating and methicillin-resistant S...
April 2017: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/28134677/are-there-any-reasons-to-change-our-behavior-in-necrotizing-fasciitis-with-the-advent-of-new-antibiotics
#15
Francesco Menichetti, Simone Giuliano, Simona Fortunato
PURPOSE OF REVIEW: The treatment of necrotizing fasciitis requires a multifaceted approach, consisting of surgical source control with immediate surgical debridement along with life support, clinical monitoring, and antimicrobial therapy. Many drugs are now available for the treatment of this life-threatening infectious disease, and the purpose of this review is to provide the reader with an updated overview of the newest therapeutic options. RECENT FINDINGS: Because most necrotizing soft tissue infections are polymicrobial, broad-spectrum coverage is advisable...
April 2017: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/28118218/obesity-and-skin-and-soft-tissue-infections-how-to-optimize-antimicrobial-usage-for-prevention-and-treatment
#16
Mordechai Grupper, David P Nicolau
PURPOSE OF REVIEW: Skin and soft tissue infections (SSTIs) are prevalent in the obese population, with rising trend expected. Although numerous antibiotics are available for the prevention and treatment of SSTIs, their characterization in obese patients is not a regulatory mandate. Consequently, information that carries importance for optimizing the dosing regimen in the obese population may not be readily available. This review focuses on the most recent pharmacokinetic and pharmacodynamic data on this topic with attention to cefazolin for surgical prophylaxis as well as antibiotics that are active against methicillin-resistant Staphylococcus aureus (MRSA)...
April 2017: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/28078655/single-dose-oritavancin-compared-to-standard-of-care-iv-antibiotics-for-acute-bacterial-skin-and-skin-structure-infection-in-the-outpatient-setting-a-retrospective-real-world-study
#17
Patrick J Anastasio, Pete Wolthoff, Annmarie Galli, Weihong Fan
INTRODUCTION: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs...
March 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27956417/effects-of-oritavancin-on-coagulation-tests-in-the-clinical-laboratory
#18
Adam Belley, Richard Robson, John L Francis, Dorothy M Adcock, Stefan Tiefenbacher, Christopher M Rubino, Greg Moeck, David Sylvester, Michael N Dudley, Jeffery Loutit
Previous studies have shown that some lipoglycopeptide and lipopeptide antimicrobial agents may cause falsely elevated values for some phospholipid-dependent coagulation tests. The effect of oritavancin, a lipoglycopeptide antibiotic, on coagulation test results was explored using pooled human plasma samples spiked with drug and in a clinical study after an infusion of a single 1,200-mg intravenous dose of oritavancin in normal healthy volunteers. Pooled plasma with oritavancin added ex vivo showed concentration-dependent prolongation of prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), and dilute Russell viper venom time (DRVVT) test results...
February 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27939809/prevalence-of-macrolide-lincosamide-resistance-and-multidrug-resistance-phenotypes-in-streptococcal-isolates-causing-infections-in-european-hospitals-evaluation-of-the-in-vitro-activity-of-oritavancin-and-comparator-agents
#19
Rodrigo E Mendes, Mariana Castanheira, David J Farrell, Robert K Flamm, Helio S Sader, Ronald N Jones
The aim of this study was to evaluate the prevalence of resistance to erythromycin alone (M) and to erythromycin and clindamycin (cMLSB) as well as multidrug resistance (MDR) phenotypes (resistance to at least three classes of drugs) among clinical enterococci from European countries and adjacent geographic regions. The in vitro activity of oritavancin against these isolates was also evaluated. A total of 2569 streptococci collected from 12 European countries as well as Russia, Turkey and Israel were included...
November 2, 2016: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/27904526/new-agents-approved-for-treatment-of-acute-staphylococcal-skin-infections
#20
Jan Tatarkiewicz, Anna Staniszewska, Magdalena Bujalska-Zadrożny
Vancomycin has been a predominant treatment for methicillin-resistant Staphylococcus aureus (MRSA) infections for decades. However, growing reservations about its efficacy led to an urgent need for new antibiotics effective against MRSA and other drug-resistant Staphylococcus aureus strains. This review covers three new anti-MRSA antibiotics that have been recently approved by the FDA: dalbavancin, oritavancin, and tedizolid. The mechanism of action, indications, antibacterial activity profile, microbial resistance, pharmacokinetics, clinical efficacy, adverse effects, interactions as well as available formulations and administration of each of these new antibiotics are described...
December 1, 2016: Archives of Medical Science: AMS
keyword
keyword
30796
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"